See the DrugPatentWatch profile for Prasugrel
What is prasugrel, and what is it used for?
Prasugrel is an antiplatelet medicine (a P2Y12 inhibitor) used to help prevent blood clots in certain patients who have coronary artery disease and are undergoing percutaneous coronary intervention (PCI) (commonly in the setting of acute coronary syndrome). It works by making platelets less able to form clots, lowering the risk of heart attack and other clot-related events after PCI.
How does prasugrel work compared with other antiplatelet drugs?
Prasugrel blocks the P2Y12 receptor on platelets, which reduces adenosine diphosphate (ADP)-driven platelet activation and aggregation. In practice, it is used as part of dual antiplatelet therapy (typically with aspirin) after PCI.
If you are comparing it to clopidogrel or ticagrelor, the key difference is which P2Y12 inhibitor class is used and how each drug behaves (including metabolism/activation pathways and bleeding-risk tradeoffs).
Who should not take prasugrel (important safety restrictions)?
Prasugrel has well-known safety limitations. Many prescribing guidelines restrict use in patients with a history of stroke or transient ischemic attack (TIA) and in certain high-bleeding-risk situations. It is also used more cautiously in patients at higher bleeding risk and in lower body weight groups.
What does the prescribing and dosing look like (typical pattern)?
Prasugrel is generally taken once daily after a loading dose during the PCI period, then continued as part of dual antiplatelet therapy for a prescribed duration based on the clinical scenario and bleeding risk. The exact regimen and duration depend on the patient’s risk profile and the treatment plan.
What side effects do patients ask about?
The most important side effect patients worry about is bleeding. Prasugrel can increase the risk of bleeding, including serious bleeding events. Other adverse effects can occur, but bleeding risk is the central concern clinicians manage when deciding whether prasugrel is the right choice.
How does prasugrel fit into DAPT after stent placement?
After PCI, prasugrel is used alongside aspirin to reduce the chance of stent thrombosis and recurrent ischemic events. The planned length of dual antiplatelet therapy reflects a balance between preventing clotting and minimizing bleeding.
Is prasugrel still under patent protection, and are there generics?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help you see when generic or biosimilar competition might be possible for a specific product and market. Check the prasugrel entry on DrugPatentWatch.com for the latest patent status details: https://www.drugpatentwatch.com/
What alternatives exist if prasugrel is not appropriate?
Common alternatives include other P2Y12 inhibitors (such as clopidogrel or ticagrelor), chosen based on bleeding risk, prior stroke/TIA history, drug interactions, and clinical factors. The “best” choice depends on patient-specific risk and how urgently platelet inhibition is needed after PCI.
Sources
- DrugPatentWatch.com (prasugrel patent/exclusivity tracking)